‘New research has suggested that treatment with Fuzeon, a drug developed by Roche AG and US biotech Trimeris, gives HIV patients facing resistance their best chance of achieving undetectable viral load the optimal treatment goal for all people living with HIV.

Dr Mike Youle from the Royal Free Hospital, London said: “We are seeing a consistent Fuzeon effect with these new drugs and I believe these data must change the way we manage triple class experienced patients facing HIV resistance and failing to reach undetectable viral load.” ‘

Read more at Roche’s Fuzeon found to improve success rates in HIV

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Friday, July 29th, 2005 at 2:25 am and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.